Please assess the completion status of the following clinical trial:

Trial Title: A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects who voluntarily sign the informed consent.~* Subject has successfully completed the treatment phase of the preceding open-label year 1 study.~Exclusion Criteria:~* Subject is using or will use investigational medications, except as approved by Abbott.~* Subject has prematurely discontinued his/her combination therapy administered in the preceding open-label year 1 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 + rosuvastatin calcium (Type: EXPERIMENTAL): None
- ABT-335 + simvastatin (Type: EXPERIMENTAL): None
- ABT-335 + atorvastatin calcium (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).